Chalcogen Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/254.07)
-
Publication number: 20100261695Abstract: The present invention generally relates to the treatment of onychomycosis. More specifically, it relates to combination therapies for the treatment of onychomycosis and related compositions. In a composition aspect, the present invention provides a composition for the treatment of onychomycosis, wherein the composition includes Ciclopirox and at least one other antifungal agent. In a method aspect, the present invention provides a method for treating onychomycosis in a patient suffering from the disease. The method involves topically administering a composition to at least one toe or fingernail of the patient and the composition includes Ciclopirox and at least one other antifungal agent.Type: ApplicationFiled: April 9, 2010Publication date: October 14, 2010Inventor: Reza BABAPOUR
-
Publication number: 20100261685Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole.Type: ApplicationFiled: November 4, 2008Publication date: October 14, 2010Inventors: Jason Shaun Burry, Richard Livesey Evans, Caroline Alexandra Hall, Ezat Khoshdel, Colina MacKay
-
Publication number: 20100255016Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: April 5, 2010Publication date: October 7, 2010Inventors: Shalaby W. Shalaby, David Ingram, Georgios T. Hilas, Sheila Nagatomi
-
Publication number: 20100256081Abstract: Bioactive, hydroforming luminal liner compositions are formed of high molecular weight crystalline, absorbable copolyesters dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: April 5, 2010Publication date: October 7, 2010Inventors: Shalaby W. Shalaby, Kenneth David Gray, Georgios T. Hilas
-
Publication number: 20100240618Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: September 8, 2009Publication date: September 23, 2010Applicant: ChemoCentryx, Inc.Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subhabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi, Wei Chen, Penglie Zhang
-
Publication number: 20100234352Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: ApplicationFiled: January 29, 2010Publication date: September 16, 2010Inventors: Bing-Yan Zhu, Shawn M. Bauer, Zhaozhong J. Jia, Yonghong Song, Gary D. Probst, Yanchen Zhang, Robert M. Scarborough
-
Patent number: 7795265Abstract: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.Type: GrantFiled: April 10, 2007Date of Patent: September 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Richard Berger, Scott Edmondson, Alexa Hansen, Cheng Zhu
-
Publication number: 20100221343Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.Type: ApplicationFiled: May 12, 2010Publication date: September 2, 2010Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Keith P. Johnston, Joshua Engstrom, Jasmine Tam, Alan Watts
-
Publication number: 20100222311Abstract: Described herein are formulations of active pharmaceutical ingredients, where the active pharmaceutical ingredients or drugs are included in a solid suspension with one or more solid additives. The formulations described herein are useful for formulating any drug or active pharmaceutical ingredient, including those that have limited solubility in organic and/or aqueous solvent systems.Type: ApplicationFiled: October 17, 2008Publication date: September 2, 2010Applicant: PURDUE RESEARCH FOUNDATIONInventors: Markus Thommes, Rodolfo Pinal, Teresa M. Carvajal
-
Publication number: 20100215775Abstract: The invention relates to the use of C10-C14-alkane-1,2-diols, in particular 1,2-decanediol, 1,2-dodecanediol and/or 1,2-tetradecanediol, in the preparation of a composition for the prophylaxis and/or treatment of Malassezia-induced dandruff formation, as well as to cosmetic and/or dermatological preparations comprising C10-C14-alkane-1,2-diols.Type: ApplicationFiled: October 12, 2007Publication date: August 26, 2010Applicant: SYMRISE GmbH & Co. KGInventors: Gerhard Schmaus, Sabine Lange
-
Publication number: 20100216776Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.Type: ApplicationFiled: August 10, 2006Publication date: August 26, 2010Inventors: Anne Reba Bresnick, Sarah Claire Garrett
-
Publication number: 20100210518Abstract: Diacyl lipid-polymer conjugates are used to enhance the solubility of lipophilic drugs in aqueous solution. The conjugates comprise a backbone, two lipophilic acyl groups and a hydrophilic polymer.Type: ApplicationFiled: January 22, 2010Publication date: August 19, 2010Inventors: Brian Charles Keller, Nian Wu
-
Publication number: 20100209368Abstract: Various embodiments of the present invention are directed to hair-loss, and include treatments and preparations. Embodiments of the present invention include bactericides, combinations of bactericides and fungicides, combination of bactericides and vasodilators, and combinations of bactericides, fungicides, and vasodilators that are delivered topically to pilosebaceous units within the scalps of persons suffering from hair loss. The treatment kills or controls microbes that disrupt hair growth by changing, inhibiting, or interrupting one or more biological functions of the pilosebaceous units. Certain embodiments of the present invention contain additional active and inactive ingredients, including anti-inflammatory agents, carriers, emulsifiers, antioxidants, and other such substances.Type: ApplicationFiled: February 11, 2010Publication date: August 19, 2010Inventor: Joseph F. Walsh
-
Patent number: 7772230Abstract: The present invention provides a chroman compound of formula (I) and its pharmaceutical salt, methods of its preparation and its pharmaceutical applications. Wherein: X is O or S; n is for 2, 3 or 4; R1 is 6-substituted or 7-substituted halogen, C1-4alkyl, C1-4alkoxyl, benzyloxy, carbamoyl; R2 is nitrogen-containing five-membered or six-membered substituted heterocyclic ring selected from piperidinyl, morpholinyl, N-methyl-piperazinyl, N-(2-ethoxyl)piperazinyl, pyrrolyl, pyrazolyl or imidazolyl. The compounds are useful to prepare medicaments for treating cardiovascular diseases, their preparation employs mild reaction conditions, the raw material are plenty and easy to be obtained, and the operation and post-treatment in the preparation are simple.Type: GrantFiled: October 25, 2007Date of Patent: August 10, 2010Assignee: China Pharmaceutical UniversityInventors: Qidong You, Lvpei Du, Minyong Li, Lin Xia
-
Publication number: 20100184714Abstract: A composition comprises a mixture of a silicone and a first solvent, a drug, such as a hydrophilic or lipophilic pharmaceutical agent, a salt of a dialkyl sulfosuccinate, such as dioctyl sodium sulfosuccinate (DOSS), and a second solvent, such as an alcohol. The salt of a dialkyl sulfosuccinate solubilizes the drug. The composition can be topically applied to a substrate, such as skin, for delivering the drug. Drugs with a wide solubility range are soluble and compatible in the composition without separation or crystallization of the drugs occurring.Type: ApplicationFiled: July 11, 2008Publication date: July 22, 2010Inventors: Victor Albert Raul, Linda Sue Nartker
-
Patent number: 7759352Abstract: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.Type: GrantFiled: April 10, 2007Date of Patent: July 20, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Joseph L. Duffy, Scott Edmondson, Hansen Alexa, Cheng Zhu
-
Publication number: 20100178337Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.Type: ApplicationFiled: December 18, 2009Publication date: July 15, 2010Applicant: Flamel TechnologiesInventors: Rémi MEYRUEIX, Rafael Jorda, Gauthier Pouliquen, You-Ping Chan, Olivier Breyne
-
Publication number: 20100179169Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: ApplicationFiled: January 15, 2010Publication date: July 15, 2010Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. Davis
-
Publication number: 20100179115Abstract: The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.Type: ApplicationFiled: May 2, 2007Publication date: July 15, 2010Applicant: Corcept Therapeutics, Inc.Inventor: Joseph Belanoff
-
Publication number: 20100168128Abstract: The present invention provides a method of inhibiting an androgen receptor by administering a compound of Formula I: or a compound of Formula II: wherein R1, R2, R3 and R8 are each independently hydrogen or C1-6 alkyl. R4 is absent or is hydrogen, C1-6 alkyl or C1-6 alkyl-OH. R5 is hydrogen, C1-6 alkyl or —NR6R7. R6 and R7 are each independently hydrogen or C1-6 alkyl, or are combined with the nitrogen to which they are attached to form a heterocycloalkyl having from 5 to 7 ring members. L is a linker of C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene or C3-6 cycloalkylene. The compounds of Formula I include the salts, hydrates and prodrugs thereof. Each R9 is H, C1-6 alkyl, —OH or —O—C1-6 alkyl. The compounds of Formulas I and II include the salts, hydrates and prodrugs thereof. By administering the compound of Formula I or II, the method inhibits the androgen receptor.Type: ApplicationFiled: March 4, 2010Publication date: July 1, 2010Applicant: The Regents of the University of CaliforniaInventors: Marc Diamond, Jeremy Jones, Adam Renslo
-
Publication number: 20100144712Abstract: A triazole derivative of formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.Type: ApplicationFiled: June 12, 2008Publication date: June 10, 2010Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CHEMON INC.Inventors: Bum Tae Kim, Yong Ki Min, Jung Nyoung Heo, Hyuk Lee, Sung Youn Chang, No Kyun Park, Si-Whan Song, Jung-Ja Oh
-
Patent number: 7732450Abstract: A pharmaceutical composition suitable for topical application comprising ketoconazole in a solution which comprises: (i) 13 to 50 wt % water; (ii) 45 to 85 wt % of an alcohol having a boiling point of less than 100° C.; and (iii) 2 to 30 wt % of a non-volatile, water miscible, non-ionic surface active agent; the ketoconazole being present in an amount of 0.5 to 3 st % relative to components (i), (ii) and (iii).Type: GrantFiled: August 14, 2001Date of Patent: June 8, 2010Assignee: Boult Wade TennantInventors: Martin Whitefield, Andrew James Dixon, Susan Colette Temple
-
Publication number: 20100137333Abstract: An antifungal composition is provided according to the present invention. The antifungal composition comprises an effective amount of an antifungal component to provide antifungal properties to skin tissue, an effective amount of a skin bonding polymer component to provide a sustained release of the antifungal component over a prolonged period of time after application of the antifungal treatment composition to skin tissue, and water. A method for using the antifungal composition is provided.Type: ApplicationFiled: October 19, 2007Publication date: June 3, 2010Inventor: James A. Roszell
-
Publication number: 20100129468Abstract: The invention relates to a composition in the form of an emulsion that can be expanded by an aerosol dispenser, characterised in that it comprises from 15 to 20 volume % of alcohol, from 1 to 10 volume % of C3-C8 polyolen, a thickening agent, at least one non-ionic surfactant, a wetting agent, and one or more active ingredients dissolved or in suspension; the invention also relates to the medical and cosmetic applications thereof.Type: ApplicationFiled: April 17, 2008Publication date: May 27, 2010Applicant: Pierre Fabre Dermo-CosmetiqueInventors: Michel Jeanjean, Nadine Senegas
-
Publication number: 20100129434Abstract: The invention provides a composition including at least one iron chelating compound and at least one antifungal agent. The composition can include the iron chelating compounds deferiprone or deferasirox. An antifungal agent included in the composition can include a polyene antifungal agent, an azole antifungal agent or an echinocandin antifungal agent. The invention also provides a method of treating or preventing a fungal condition. The method includes administering to an individual having, or susceptible to having, a fungal condition a therapeutically effective amount of at least one iron chelating compound for a sufficient time to reduce the severity of a fungal condition, wherein the iron chelating compound comprises a non-siderophore or non-xenosiderophore relative to the fungal condition.Type: ApplicationFiled: July 13, 2007Publication date: May 27, 2010Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Ashraf S. Ibrahim, Brad J. Spellberg, John Edwards
-
Publication number: 20100120768Abstract: The invention features methods, kits, and compositions for generating new hair follicles and growing hair on a subject.Type: ApplicationFiled: September 27, 2007Publication date: May 13, 2010Inventors: David Steinberg, Kevin Pojasek, Stephen Prouty, George Cotsarelis, Mayumi Ito
-
Publication number: 20100113607Abstract: A method for the topical treatment of nail diseases, e.g. onychomycosis, after preparation of the infected nail with a laser beam.Type: ApplicationFiled: December 11, 2009Publication date: May 6, 2010Inventor: Alfredo Emilio Bruno-Raimondi
-
Publication number: 20100099724Abstract: The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising fungicidal triazoles. It also relates to formulations comprising one or more fungicidal triazoles and alkoxylated amines. These formulations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, biodegradable material and textiles against deterioration due to the action of fungi.Type: ApplicationFiled: December 11, 2009Publication date: April 22, 2010Applicant: JANSSEN PHARMACEUTICA N.V.Inventors: Johannes Gerardus Tiedink, Emmanuel Philippe Thierry Paris, Mark Arthur Josepha Van der Flaas
-
Publication number: 20100093755Abstract: Treatment of patients with the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.Type: ApplicationFiled: October 2, 2007Publication date: April 15, 2010Applicant: CORTENDO INVEST AB,Inventor: Timothy Andrew Stewart
-
Publication number: 20100092479Abstract: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).Type: ApplicationFiled: August 17, 2009Publication date: April 15, 2010Applicant: CombinatoRx (Singapore) Pte. Ltd.Inventors: Lisa M. Johansen, Christopher M. Owens
-
Publication number: 20100086611Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 ?m as measured by laser diffractometry.Type: ApplicationFiled: March 30, 2009Publication date: April 8, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Barrett Rabinow, Randy White, Chong-Son Sun, Joseph Chung Tak Wong, James E. Kipp, Mark J. Doty, Christine Rebbeck, Pavlos George Papadopoulos
-
Publication number: 20100081669Abstract: Disclosed is a pressure-sensitive adhesive matrix patch device for treatment or prevention of fungal toenails or fingernails or foot infections comprising an antifungal agent or two or more antifungals in combination and adhesively secured to a dorsal site of an infected palm or foot, rather than an area of infection and surrounding skin. A method for the transdermal treatment or prevention of fungal toenails or fingernails or foot infections with an antifungal agent is also disclosed, the method comprising adhesively securing to a dorsal site of an infected palm or foot a pressure-sensitive adhesive matrix patch device for a time sufficient to deliver an effective amount of the antifungal agent to an area of infection.Type: ApplicationFiled: September 30, 2009Publication date: April 1, 2010Applicant: Taiwan Biotech Co., Ltd.Inventors: Kuo-Hua Yang, Yung-Jin Lee, Li-Chin Lin
-
Publication number: 20100068307Abstract: A foaming gelled composition in the form of a stable oil-in-water microemulsion comprising a fatty phase of microdroplets dispersed in an aqueous phase and a dermatological active ingredient, characterized in that it comprises a surfactant system comprising:—at least one ethoxylated nonionic surfactant;—at least one cosurfactant for stabilizing the ethoxylated nonionic surfactant;—at least one nonethoxylated hydrophilic nonionic surfactant;—at least one foaming agent chosen from the group of anionic surfactants.Type: ApplicationFiled: January 25, 2008Publication date: March 18, 2010Applicant: PIERRE FABRE DERMO-COSMETIQUEInventor: Francoise Nielloud
-
Patent number: 7678791Abstract: Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.Type: GrantFiled: July 12, 2007Date of Patent: March 16, 2010Assignee: Cumbre IP Ventures, L.P.Inventors: Charles Z. Ding, In Ho Kim, Jiancheng Wang, Zhenkun Ma, Yafei Jin, Keith D. Combrink, Genliang Lu, A. Simon Lynch
-
Publication number: 20100056542Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them.Type: ApplicationFiled: September 4, 2009Publication date: March 4, 2010Applicant: Ardea BiosciencesInventors: Esmir Gunic, Jean-Luc Girardet, David A. Paisner
-
Publication number: 20100056543Abstract: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.Type: ApplicationFiled: November 13, 2009Publication date: March 4, 2010Applicant: Enzon Pharmaceuticals, Inc.Inventor: Hong ZHAO
-
Publication number: 20100016271Abstract: A hair conditioning composition comprising a cationic surfactant, triglyceride oil, and an anti dandruff agent.Type: ApplicationFiled: July 2, 2007Publication date: January 21, 2010Inventors: Wanlin Chang, Kanjana Phattarasakul, Busaraporn Samran, Jie-bing Zhu
-
CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS
Publication number: 20100008990Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.Type: ApplicationFiled: July 6, 2009Publication date: January 14, 2010Applicant: K.U. Leuven Research & DevelopmentInventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck -
Publication number: 20100003332Abstract: A powder comprising nanoparticles of a sparingly water-soluble drug prepared in accordance with the present invention exhibits enhanced bioavailability without generating adverse side effects caused by impurities, while the nano-particle size of the drug remains unchanged when administered. Accordingly, the powder can be useful for the development of a formulation of a sparingly water-soluble drug for oral and parenteral administration.Type: ApplicationFiled: July 26, 2007Publication date: January 7, 2010Applicant: Amorepacific CorporationInventors: Joon Ho Bae, Jong Hwi Lee, Hyeok Lee, Jung Ju Kim
-
Publication number: 20090324725Abstract: The present invention provides a PEG-modified HAP having a high degree of safety and novel functions by modifying the surface of hydroxyapatite particles with a polyethylene glycol derivative, applications thereof, and a production process of the same. The PEG-modified HAP of the present invention is a substance in which hydroxyapatite having a particle diameter of 50 ?m to 10 nm is bonded to a polyethylene glycol derivative having a carboxyl group as a terminal functional group through —O(CO) bonds, and the carbon content thereof is 10 to 0.1%. In addition, the present invention is a substance composed of this substance and a pharmaceutical active ingredient or pharmaceutical additive, in which the weight ratio of the pharmaceutical active ingredient is 1 to 30%, and the substance is obtained by treating hydroxyapatite having a particle diameter of 50 ?m to 10 nm and an active ester of polyethylene glycol derivative having a carboxyl group as a terminal functional group in an anhydrous organic solvent.Type: ApplicationFiled: January 23, 2009Publication date: December 31, 2009Applicant: EBARA CORPORATIONInventors: Kazunao MASUBUCHI, Junichi Minowa, Kazuo Watanabe, Isao Umeda
-
Publication number: 20090311325Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.Type: ApplicationFiled: April 10, 2007Publication date: December 17, 2009Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENTInventors: Sandrien Janssens, Guy Van Den Mooter
-
Publication number: 20090304769Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.Type: ApplicationFiled: June 4, 2007Publication date: December 10, 2009Inventors: Eric J. Kunkel, Evangelos Hytopoulos, Ivan Plavec
-
Publication number: 20090298847Abstract: The present invention relates to a method for preparing an itraconazole-containing solid dispersion. The itraconazole-containing solid dispersion according to the preparing method of the present invention has both improved solubility and rapid dissolution rate so that it has an excellent bioavailability. The itraconazole-containing solid dispersion of the present invention is also independent of pH variation of human stomach so that it can minimize the absorption variation of intra- and inter-individuals. In addition, the itraconazole-containing solid dispersion according to the preparing method of the present invention is stable for a long time. The present invention also provides an economical and environment-friendly method for manufacturing an itraconazole-containing composition because the method adds a lactic acid in a solution comprising itraconazole to decrease the amount of an organic solvent needed to dissolve itraconazole.Type: ApplicationFiled: June 24, 2005Publication date: December 3, 2009Applicant: CTC BIO, INC.Inventors: Hong-Ryeol Jeon, Se-Geun Yu, Bong-Sang Lee, Se-Heum Oh, Jeong-Seo Park, Dong-Ryun Oh, Do-Woo Kwon
-
Publication number: 20090298848Abstract: Pharmaceutical compositions comprising the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates are useful to increase cardiolipin synthesis and for the treatment of Barth Syndrome, diabetic myopathy, cardiomyopathy associated with aging, mitochondrial disease, and other conditions and disorders where cardiolipin deficiency plays a causative or symptomatic role.Type: ApplicationFiled: April 18, 2007Publication date: December 3, 2009Applicant: CORTENDO INVEST AB,Inventor: Timothy Andrew Stewart
-
Publication number: 20090291132Abstract: Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailability. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydrofurans in the bilayer.Type: ApplicationFiled: May 15, 2009Publication date: November 26, 2009Inventors: Brian Charles Keller, Nian Wu
-
Publication number: 20090285865Abstract: Palatable, solid oral formulations or compositions include at least one bioactive agent capable of chemical sterilization of human and animal males. Depending on the targeted species, the bioactive formulations comprise suitable additives, excipients, water-swellable compositions, and/or processing aids and can be made into uncoated or coated forms to modulate the release profile of the bioactive agents. Among the bioactive agents are zinc compounds and complexes and organic drugs with established pharmacological activities, which are traditionally unrelated to any form of contraception.Type: ApplicationFiled: May 14, 2009Publication date: November 19, 2009Inventor: Shalaby W. Shalaby
-
Publication number: 20090280112Abstract: Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor.Type: ApplicationFiled: May 1, 2009Publication date: November 12, 2009Inventors: IRA D. Goldfine, Jack F. Youngren, Michael J. Campbell, Betty A. Maddux, John A. Kerner, Charles J. Ryan
-
Publication number: 20090281117Abstract: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.Type: ApplicationFiled: April 10, 2007Publication date: November 12, 2009Inventors: Joseph L. Duffy, Scott Edmondson, Hansen Alexa, Cheng Zhu
-
Publication number: 20090269394Abstract: The present invention relates to methods for treating and completely curing fungal, yeast and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition.Type: ApplicationFiled: April 27, 2009Publication date: October 29, 2009Inventors: James R. Baker, JR., Mary R. Flack, Susan Ciotti, Joyce A. Sutcliffe
-
Publication number: 20090253712Abstract: A pharmaceutical composition includes: an azole derivative solubilized in a solvent system including: a) water, b) pH-adjuster, c) co-solvent and d) surfactant.Type: ApplicationFiled: April 3, 2009Publication date: October 8, 2009Applicant: SEMMELWEIS EGYETEMInventors: Kristof KOVACS, Krisztina LUDANYI, Gyorgy STAMPF, Istvan ANTAL, Imre KLEBOVICH